Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
All sales are subject to our Research-Only Terms of Service
The rates of major abdominal surgery were comparable between groups, and there was no sign of increased surgical risk
Presented for research literature review only Basaki M et al
GLP-1s can increase insulin production, delay gastric emptying, promote beta-cell proliferation, and decrease appetite
In the supply - demand pattern of strong demand and weak supply for GLP - 1 weight - loss drugs, tirzepatide, relying on its advantages in efficacy and channels, effectively absorbed some of the overflowing demand, achieving double growth in sales and market share, and thus establishing its core position in the GLP - 1 weight - loss drug market
![PDF] GLP-1 receptor agonists: a review of head-to-head clinical studies](https://figures.semanticscholar.org/d6e214df491bd874c451833804c97c101868701d/4-Figure2-1.png)
